Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H31N3OS |
| Molecular Weight | 409.587 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN4CCN(C)CC4)C2=C1
InChI
InChIKey=DVLBYTMYSMAKHP-UHFFFAOYSA-N
InChI=1S/C24H31N3OS/c1-3-7-22(28)19-10-11-24-21(18-19)27(20-8-4-5-9-23(20)29-24)13-6-12-26-16-14-25(2)15-17-26/h4-5,8-11,18H,3,6-7,12-17H2,1-2H3
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6126230 |
|||
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
211 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860932/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTAPERAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1990 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860932/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTAPERAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860932/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTAPERAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes | yes (co-administration study) Comment: Coadministration of Desipramine (CYP2D6 substrate) increased Butaperazine concentration. |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QN05AB09
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
||
|
WHO-ATC |
N05AB09
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
||
|
NCI_THESAURUS |
C66884
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
||
|
NCI_THESAURUS |
C29710
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB06007MIG
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
C084595
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
C81090
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
211-493-9
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
TXP4T9106S
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
BUTAPERAZINE
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
1432
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
DB13213
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
12598
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
443
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
DTXSID1022712
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
653-03-2
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL1697826
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
3297
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
100000088497
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | |||
|
m2789
Created by
admin on Mon Mar 31 17:52:21 GMT 2025 , Edited by admin on Mon Mar 31 17:52:21 GMT 2025
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)